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expected, diabetes has a negative impact on diabetic patient’s
quality of life, some variables were identiﬁed to contribute to a
worst perceived QoL.
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OBJECTIVES: Previous research has shown that generic
patient-reported outcome (PRO) measures underestimate the
impact of polycystic ovary syndrome (PCOS) on quality of life
(QoL). Following recent regulatory guidance, our review aimed
to identify PCOS-speciﬁc QoL measures and establish whether
their development history and measurement properties support
their use in clinical trials. METHODS: A systematic search of
MEDLINE and PsycINFO was conducted using terms synony-
mous with “PCOS” in combination with terms associated with
“QoL” to identify PCOS-speciﬁc QoL measures completed by
the patient. Articles were included if written in the English lan-
guage and published since 1998. Following identiﬁcation of
measures, further searches were undertaken using the question-
naire name and abbreviation to explore its use, development
history and demonstrated measurement properties. RESULTS:
Sixty-ﬁve abstracts were identiﬁed and screened. Of these, 19
reported quantitative studies using a variety of PRO question-
naires (most commonly the SF-36). Only one PCOS-speciﬁc
QoL questionnaire was identiﬁed: the PolyCystic Ovary Syn-
drome Questionnaire (PCOSQ). A search for use of the PCOSQ
since its development publication (1998) returned ten papers,
which were included in our review. The PCOSQ’s development
history (including conceptual and endpoint models) is inad-
equate, with recent studies indicating that the PCOSQ does not
have good content validity, e.g. the impact of acne on QoL is
notably missing. The PCOSQ subscales demonstrate acceptable
levels of reliability (0.54–0.93) and partial known-groups valid-
ity (p < 0.05 between treatment and placebo groups on three of
the ﬁve PCOSQ domains) as well as convergent/divergent valid-
ity with other PRO instruments. Responsiveness to change has
been variable and minimally important differences (MIDs) have
not been established. CONCLUSIONS: The PCOSQ has domi-
nated research relating to the impact of PCOS on QoL.
However, in order to fulﬁl current regulatory requirements,
additional research is required to ensure its comprehensibility
and sensitivity prior to including the PCOSQ in a clinical trial
programme.
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OBJECTIVES: Quality of life (QoL) is recognised widely as an
important health outcome in diabetes, where the daily burden of
self-management places great demands on the individual.
However, the concept of QoL remains ambiguous and poorly
deﬁned. The aim of our review was to clarify the measurement of
QoL in terms of conceptualisation, terminology and psychomet-
ric properties, to review the instruments that have been used
most frequently to assess QoL in diabetes research and make
recommendations for how to select measures appropriately.
METHODS: A systematic literature search was conducted to
identify the ten measures most frequently used to assess QoL in
diabetes research studies and clinical trials from 1995 to March
2008. RESULTS: A total of 6,085 abstracts were screened for
instrument names. An assessment of content validity indicated
that, of the ten instruments most frequently used to assess
“QoL”, only three actually do so (i.e. the generic WHOQoL, and
the diabetes-speciﬁc DQOL and ADDQoL). The remaining seven
instruments more accurately measure health status (SF-36,
EQ-5D), treatment satisfaction (DTSQ) and psychological well-
being (BDI, HADS, W-BQ, PAID). In addition, development
histories are variable, as is the extent to which psychometric
properties have been established in diabetes. CONCLUSIONS:
No single measure can suit every purpose or application but
researchers have repeatedly and erroneously used inappropriate
instruments to assess QoL in diabetes. Any conclusions related to
QoL drawn from such assessments, therefore, are fundamentally
ﬂawed. If we value QoL as a goal of therapy, then we must ensure
that the instruments we use to assess effectiveness are both valid
and reliable. Investigators need to be clear about exactly what
they wish to assess when selecting a measure (matching concept
to content) and ensure appropriate interpretation. When a holis-
tic evaluation is required, using two or three brief measures in
combination may offer a broader perspective.
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OBJECTIVES: To assess the HRQoL and treatment satisfaction
in diabetic patients and analyze their relationship with the gly-
cemic control. METHODS: An epidemiological, cross sectional,
naturalistic study was carried out in Spanish Primary Care
centres. Patients >18 years with diabetes mellitus type 1 (T1DM)
or type 2, with insulin treatment (T2DM-i) or not (T2DM-n.i),
were enrolled in the study (consecutive cases sampling). The last
value of glycosylated hemoglobin (HbA1c) of each patient,
reported in 2006, deﬁned the glycemic control as satisfactory
(HbA1c  7%) or unsatisfactory (HbA1c > 7%). HRQoL was
obtained from EQ-5D questionnaire and its VAS subscale and TS
from the Diabetes Treatment Satisfaction Questionnaire (SATQ-
s). Differences between groups were determined by Chi-Square
and t-student tests and ANCOVA models. RESULTS: A total of
679 patients were enrolled in the study: 52.4% female; age 65.2
(13.7); BMI 28.81 (4.66); type of diabetes: 11.5% T1DM,
26.2% T2DM-i and 62.3% T2DM-n.i; mean time from diag-
noses 11.9 (9.25) years. 53% of patients achieved satisfactory
control (T1DM: 29.5%, T2DM-i: 31.5% and T2DM-n.i:
63.8%; p < 0.001). EQ-5D score were 0.76 (0.22); T1DM group
obtained a little higher score, 0.86 (0.18), than T2DM groups
(p < 0.05) and no differences were found between glycemic
control groups. VAS total score was 64.48 (17.93); patients with
satisfactory control obtained a higher score, 65.72 (17.72) vs
63.30 (18.22); p < 0.05. T1DM and T2DM-n.i groups reported
a VAS score higher than T2DM-i: 66.41 (17.90) vs. 66.28
(17.33) vs 59.47 (18.48) respectively. SATQ-s total score was
25.01 (6.67); T2DM-n.i group was more treatment-satisﬁed than
T2DM-i and T1DM: 26.15 (5.85) vs 22.97 (7.63) and 23.47
(7.10) respectively. Satisfactory control group also obtained a
higher score than unsatisfactory control group: 25.79  6.28 vs
24.39  6.88; p < 0.05. CONCLUSIONS: Patients with satisfac-
tory glycemic control obtained better values of HRQoL (VAS)
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and TS. T1DM and T2DM-n.i reported better values of HRQoL
and T2DM-n.i better TS.
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OBJECTIVES: Patients play a major role in the management of
type 2 diabetes since this depends not only on medication but
also on behavioural modiﬁcations in areas such as nutrition,
physical activities and weight loss. Therefore, patients’ under-
standing of the disease and its management are particularly
important to ensure high compliance and reduce risk of late
complications. The aim of this project was to develop a tool for
clinical practice to 1) renew patient-clinician communication on
type 2 diabetes management; 2) reinforce patients’ motivation
by rectifying or perfecting their knowledge; and 3) agree
achievable micro-objectives between patients and clinicians.
METHODS: Face-to-face semi-structured interviews were con-
ducted with 10 adult type 2 diabetes patients by a psychologist
in parallel with interviews with 5 general practitioners,
involved in the management of type 2 diabetic patients. All
interviews were recorded and transcribed, in order to analyse
the content and organise it by domains. Based on these ﬁndings
and on feedback from experts, a ﬁrst version of the tool was
developed. This was tested using a cognitive interview method
with 5 type 2 diabetics, to assess the clarity, comprehension,
and relevance of each item as well as the overall acceptability
of the tool. RESULTS: Five major domains were identiﬁed as
playing a role in type 2 diabetes disease management: physical
activities, treatment, nutrition, knowledge of the disease and
knowledge of glycaemia issues. A speciﬁc module was devel-
oped around each of the 5 domains, drafting items using
patients’ verbatim expressions. The tool allows patients to
describe their beliefs, attitudes and priorities. The tool was
revised after the patient tests. CONCLUSIONS: This tool
should enhance patient-clinician communication on diabetes
management. By revealing patients’ beliefs, identifying their
goals, triggering positive changes, this tool could help clinicians
with the therapeutic education of patients. It will be tested in a
speciﬁc validation study.
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OBJECTIVES: Diabetes is a common, debilitating chronic illness
with multiple impacts on patients’ lives. Critical to understand-
ing these impacts is the effect of the treatment delivery system. In
diabetes multiple systems are available; however, a patient
reported outcomes (PRO) measure assessing impacts appropriate
for all systems is not available. As a result, impacts can’t be
compared across treatments and clinical decisions targeting treat-
ments to patient needs is hampered. A well developed PRO
measure appropriate across delivery systems is critical for future
research. The purpose of the study was to understand the full
spectrum of PRO issues and develop a measure of these impacts
across all delivery systems. METHODS: Qualitative data was
collected from literature, experts and patients and transcripts
thematically coded. Additionally, validation ﬁndings from four
previously developed diabetes PRO measures (ITSQ, Diab-
MedSat, Diabetes Productivity, Diabetes Symptom) were exam-
ined for relevance. Based on a synthesis of all information, a
conceptual model of the impact of treatment applicable to all
delivery systems was developed and a PRO measure generated.
RESULTS: A total of 143 patients in three countries (US, UK,
Australia) treated with the full range of treatment options (oral,
syringe, pen, inhaled, pump) were interviewed regarding the
impact of diabetes treatment on functioning, well-being and
health. Regardless of delivery system, common impacts of dia-
betes treatment were identiﬁed: psychological health, daily life
interference (home/work), treatment burden, device satisfaction,
perceived efﬁcacy and side effects. Key modiﬁers to this impact
(i.e., treatment history, occupation, activity level) and conse-
quences (i.e., compliance, poor productivity) were also identiﬁed.
Based on the conceptual model, a PRO impact measure (TRIM-
Diabetes) was generated with six discrete domains. CONCLU-
SIONS: The instrument development process, the full conceptual
model, and discussion of clinical implications will be presented.
This information should help clinicians identify key PRO issues
for diabetes, facilitate targeted treatments and allow for mean-
ingful measurement of treatment effect regardless of treatment
delivery system.
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OBJECTIVES: To develop concepts, domains and items for a
patient-reported outcome proﬁle measure that addresses the
behaviors, attitudes, and importance of self-managing diabetes in
patients with type 2 diabetes. This self-management proﬁle
complements traditional clinical outcomes to evaluate how
diabetes treatments improve self-management behaviors.
METHODS: We developed a conceptual model and conceptual
framework of patient self-management to support a patient-
reported self-management proﬁle. These models incorporate
treatment attributes identiﬁed through qualitative interviews
with patients and the review of the American Diabetes Associa-
tion (ADA) 2008 Standards of Medical Care in Diabetes. The
proﬁle consists of items measuring patient behaviors, feelings,
and attitudes about the importance of managing their blood
glucose, medication regimen, weight, eating, exercise, and
diabetes-related distress. Qualitative interviews were conducted
with patients with Type 2 diabetes managed with combinations
of lifestyle, oral and injectable therapy. Subjects were asked to
provide information on their most positive and problematic
experiences with treatment for their diabetes and their efforts to
manage their condition. Qualitative transcripts were coded by
like concepts and used with the ADA Standards to generate items
and develop the self management proﬁle. Additional patients
participated in cognitive interviews to address relevance and
clarity of items. RESULTS: Patients were enrolled from clinics
across the United States. Participants in the concept elicitation
interviews (n = 82) were 30–85 years of age (mean = 57.5);
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